Invention Grant
US08961957B2 Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
有权
肿瘤内引入具有抗TNF和/或抗IL-10的细胞毒性T淋巴细胞和/或NKT细胞的治疗和方法
- Patent Title: Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
- Patent Title (中): 肿瘤内引入具有抗TNF和/或抗IL-10的细胞毒性T淋巴细胞和/或NKT细胞的治疗和方法
-
Application No.: US13928844Application Date: 2013-06-27
-
Publication No.: US08961957B2Publication Date: 2015-02-24
- Inventor: Kenichiro Hasumi
- Applicant: Hasumi International Research Foundation
- Applicant Address: US DC Washington
- Assignee: Hasumi International Research Foundation
- Current Assignee: Hasumi International Research Foundation
- Current Assignee Address: US DC Washington
- Agency: Eckert Seamans Cherin & Mellott, LLC
- Agent Carol A. Marmo
- Main IPC: A01N63/00
- IPC: A01N63/00 ; A61K45/00 ; A61K47/00 ; A61K39/395 ; C12N5/0786 ; C12N5/0783 ; C07K16/24

Abstract:
The invention relates to therapy and methods of applying the therapy to cancer patients. The invention includes introducing intratumorally cytotoxic T lymphocyte and/or NKT cells, and prior to, coincident with, or following introducing intratumorally the cytotoxic T lymphocyte and/or NKT cells, introducing intratumorally anti-TNF and/or anti-IL-10 to the patient. The cytotoxic T lymphocyte and/or NKT cells can be induced by the intratumoral introduction of immature dendritic cells to the patient. This therapy of the invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients in the absence of radiation therapy.
Public/Granted literature
Information query